The investment targets a stabilized, purpose-built medical device research and development facility through a master lease structure with Kindeva Drug Delivery L.P., a global pharmaceutical CDMO as the underlying tenant. It seeks to preserve capital and generate income through a 15-year absolute net lease while positioning to benefit from life sciences sector trends and Minneapolis MSA growth for potential appreciation over a 5–9 year hold.